Friday, September 29, 2023
Friday, September 29, 2023

Contact us 561.316.3330

Peter J Brown Is Appointed President of Reverba

Reverba, a leading global patient engagement company, today announced the appointment of Peter J. Brown, MBA, as President. He brings more than 20 years of experience in life sciences, healthcare and patient engagement, with a track record of driving growth in highly complex, competitive markets and successfully scaling organizations to support expanding service and product offerings.

“We are delighted to welcome Peter to Reverba. His experience enhances the leadership team and strengthens our ability to transform the way biopharmaceutical companies think and function by incorporating compliant, patient-centered action at the core of their business,” said Cheryl Lubbert, CEO and co-founder of Reverba. “Peter brings the ideal skills we need to accelerate our growth and deliver value for healthcare organizations and patients.”

Peter J Brown joins Reverba at an exciting time, as the company is expanding its proprietary, compliant patient engagement solutions and services to connect biopharma companies with patients to amplify the impact of patient voices.

“I am excited to take on this role at Reverba, a foundational company that helped create the patient engagement space,” said Peter J Brown, President of Reverba. “I see an extraordinary opportunity for Reverba to expand the company’s offerings, built on deep understanding of secure technology solutions that enable meaningful connections with patients.”

Brown joins Reverba from his role as President, Chief Executive Officer and General Manager of Thornberry, provider of hospice and home health software solutions, where he drove market strategy, product development, operations and sales against aggressive financial and operational performance targets, leading two major platform technology initiatives and significant product enhancements. Concurrently, he was Founder and President of Proinligo Consulting, providing support to payers, providers and health systems for digital health services and engagement. He is a Fellow of the Academy for Healthcare Management and holds a Bachelor of Economics from Union College and an MBA in Management from McDonough School of Business, Georgetown University.

SourceReverba
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

MORE EXECUTIVES

CorWave Appoints Magalie Durrèche as Chief Financial Officer

Magalie Durrèche will oversee the financial management and participate in the strategic planning and fundraising of CorWave, a company developing and manufacturing a blood pump based on breakthrough technology. She succeeds Zina Hamoumi, who served as Chief Financial Officer for five years before deciding to focus on other projects.

Veracyte Names Dr Phillip G Febbo Chief Scientific Officer and Chief Medical Officer

“Phil G Febbo is an exceptional leader with a strong track record of driving successful commercialization of molecular tests through evidence development, guideline inclusion and key opinion leader support,” said Mr. Stapley. “His experience and expertise will be critical to further enhancing our ability to serve our customers and, ultimately, to transforming cancer care for patients all over the world.”

GrayMatters Health Expands US Executive Team, Including Appointment of Dr Aron Tendler as Chief Medical Office

Dr Aaron Tendler is a board-certified psychiatrist based in Palm Beach, Florida, bringing over 20 years of experience as an industry leader researching novel treatments for mental health disorders.

Carthera Appoints Dr Oern Stuge as Chairman of Board of Directors

Dr Oern Stuge brings 30+ years expertise with a wealth of experience in product development and commercial launches to support Carthera’s future growth.

Cytomos Appoints a New Director as £4 Mill Investment Sets Path for Commercialisation of Groundbreaking Cell Analysis Technology

The biotech company’s appointment of industry leader Dr Sharon Brownlow as Non-Executive Director further enhances Cytomos’ senior management team and its unique value proposition to key industry markets.

By using this website you agree to accept Medical Device News Magazine Privacy Policy